Dr. Ali Imran Amjad, MD

Dr. Amjad practices at AHN Grove City Hospital in Grove City, Pennsylvania, part of Highmark Health.

Dr. Amjad's NPI, 1568690287, was assigned on July 1, 2009. Dr. Amjad holds Pennsylvania license MD446838.

Dr. Amjad's primary practice is AHN Grove City Hospital, at 631 North Broad Street Ext., Grove City, PA 16127 in Mercer County. The practice phone is (724) 450-7000.

Dr. Amjad's primary practice is AHN Grove City Hospital in Grove City, Pennsylvania, part of Highmark Health. Dr. Amjad is also affiliated with Allegheny General Hospital. The medical group on file is Allegheny Health Network Cancer Institute. Dmand AI also links Dr. Amjad to 4 more hospitals, 1 group practice or clinic, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amjad practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Amjad's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Amjad is licensed in Pennsylvania.

CMS data shows 1,539 Medicare services from Dr. Amjad across 12 procedure codes in 2024, for 484 Medicare patients. Medicare paid $101,123 for them.

CMS counts 484 Medicare patients who saw Dr. Amjad in 2024. The largest group is 65 to 74, with 199 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.31, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amjad's median patient age at 74, with 55% women.

In 2024, Dr. Amjad wrote 2,644 Medicare Part D claims for 434 patients. 74% of them were for generic drugs. CMS names the drug for 2,293 of them, across 61 drugs with 11 or more claims each, at $2,543,452 in total drug cost. In 2023, CMS named 1,715 claims across 50 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Amjad for performance year 2024, reported as part of a group. Dr. Amjad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Amjad as offering telehealth.

Dmand AI links 13 papers to Dr. Amjad, published from 2012 to 2024. 2015 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols. Dr. Amjad has published most often in Case Rep Oncol Med. Dr. Amjad's most frequent co-authors are Rahul Atul Parikh, MD, PhD, Hira Ali, MD and Leonard Joseph Appleman, MD.

Dmand AI links Dr. Amjad to 4 clinical trials. 4 are still active or recruiting. Conditions studied include Carcinosarcoma, Fallopian Tube Diseases and Stomach Neoplasms. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 285 general payments to Dr. Amjad from 45 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 89% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,597.